Navigation Links
Lakewood-Amedex Inc. to Develop Broad Spectrum Influenza Drug to Include H1N1 and H5N1 Type A Strains
Date:8/27/2009

SARASOTA, Fla., Aug. 27 /PRNewswire/ -- Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

Lakewood-Amedex's nRNA product works by selectively silencing targeted genes in the viral genome. The company is building on the previously successful animal model study where mice infected with H1N1 type A influenza virus were given two doses of the L-A nRNA product and all survived while control and placebo dosed mice all died within six days. In addition L-A previously published a study demonstrating the effectiveness of its technology against the lethal H5N1 "bird flu" influenza virus in which a single intra-nasal dose of the company's nRNA product protected 100% of the infected chickens while placebo treated chickens all died within seven days.

Steve Parkinson, L-A's President and Chief Executive Officer, commented, "We had intended to develop our broadly applicable influ-RNA product to treat seasonal flu and as an emergency stockpile product in the event of a further outbreak of avian influenza, but due to the escalating global H1N1 pandemic and now the report of this virus having been isolated from turkeys in Chile, we feel it is critical to have a product that can target multiple strains of influenza and is useable year after year."

Mr. Parkinson explained that the L-A product does not work like a vaccine that stimulates the human host immune system to produce antibodies targeted at the specific viral strain composing the vaccine. Instead the nRNA product contains several short oligonucleotide sequences that are mirror images to unique
'/>"/>

SOURCE Lakewood-Amedex Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Karolinska Development Portfolio Company Launches GMP Facility for Particulate Manufacturing
2. New Consortium to Develop Drugs for Neglected Tropical Diseases
3. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
4. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
5. Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
6. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
8. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
9. Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value
10. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
11. ADHD Genes Found; Known to Play Roles in Neurodevelopment

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonThera...dyofitsleadproduct,PRT-201,inend-stagerenaldisease...ft(AVG)creation.TheAVGstudyrepresentsProteon,sseco...slyannouncingtheinitiationofaPhase1/2studyofPRT-20...stula(AVF)creationearlierthisyear.Proteonalsoannou...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-Fir...thatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagreedt...oftheproposedmergerbetweenAnesivaandArcionTherapeu...otescheduledtotakeplaceatthepreviouslyannouncedAne...mber3,2009at9:00a.m.PSTat400OysterPoint,Suite107A,...
(Date:11/23/2009)..., NOVATO,Calif.,Nov.23/PRNewswire-FirstCall/--Ra...sdaq: RPTP ),todayannouncedresultsfromaPhase2bclin...bitartrate("DRCysteamine")inpatientswithnephropath...UniversityofCalifornia,SanDiego("UCSD")GeneralClin...armacokineticsandpharmacodynamicsofasingledoseofDR...
Breaking Medicine Technology:Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 1Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 2Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 3Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 4Leading Blood Centers LifeSource and Central Blood Bank Spotlight a Unique Donor Population During National Hereditary Hemochromatosis Awareness Mon 51690 5Walking Biking to Work Pays Off 51688 1Walking Biking to Work Pays Off 51688 2
... /PRNewswire/ -- Results from,the primary analysis...study showed that 77 percent of treatment-experien...unavir) 600 mg tablets with,100 mg ritonavir (PREZ...regimen (OBR) of antiretroviral (ARV) agents, reac...48, compared to 68,percent of patients taking Kale...
...al in non-small cell lung cancer -, LOS ANGELES, J...netics, Inc. today announced that positive Phase I...the Journal of Clinical,Oncology suggests that low...-Complementing 1 (ERCC-1) in patient biopsies,with...cts for,sensitivity to cisplatin-based chemotherap...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
(Date:11/23/2009)...gency, said lives could be at risk , , M...m last week,s controversial recommendation that wo...or breast cancer continues, with a former head of ...men to ignore the guidelines. , "I,m saying ver...is will increase the number of women dying of brea...
(Date:11/23/2009)...ington D.C. , NewYorkCity , LosAngeles and...ndRevitalization ,, WASHINGTON,Nov.23 /PRNe...derofdialysisservices,todaywaslaudedbyD.C.official...estmentinIndustrialBankaspartofaninitiativeaimedat...stmentinWashington,D.C.ispartofthedialysiscompany,...
(Date:11/23/2009)...ington D.C. , NewYork , N.Y. , LosAngeles...rEconomicGrowthandRevitalization ,, WASHINGTON...leadingproviderofdialysisservices,todayannouncedan...sandspurrevitalizationinminoritycommunitiesacrosst...ity-ownedbanks.DaVitahasdonated$5millionthroughban...
(Date:11/23/2009)...utureLeadersinSTEMFields ,, ScholarshipandInt... c holars.org ,, WASHINGTON,Nov.23/PRNew...ithourcommunity,foundation,andcorporatepartnersthe...dolphP.Falcon,SeniorVicePresidentoftheNationalAlli...tingtodaywherePresidentObamaannouncedthecommitment...
(Date:11/23/2009)...e/-- The AmericanLegislativeExchangeCouncil (ALEC...nofstatelegislators,congratulatesSouthCarolinaStat...onalamendment toprotecttherightofindividualstomake...he24thstatewherelegislatorshaveintroduced,orwillin...iceinHealthCareAct . ,, (Logo: http://www.newsc...
Breaking Medicine News(10 mins):Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 2Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 3Health News:DaVita Launches Minority Bank Initiative with $1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities 4Health News:DaVita Launches Minority Bank Initiative with $5 Million Investment in Underserved Communities Across the Country 2Health News:DaVita Launches Minority Bank Initiative with $5 Million Investment in Underserved Communities Across the Country 3Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:South Carolina Now 24th State to Defend Health Care Choice 2
...ertain outbreak of a bird flu pandemic among human...expert.// Professor Johan Giesecke of the E...(ECDC) was speaking after chief veterinary and med... next few years, but it is certain that there will...
...near Danube Delta, Romania. But now new cases of d...The bird flu disaster is slowly creeping in all di...rgest wetland in Europe and is an important migrat... Bird flu is caused by the deadly strain H5N1. Th...
...dent has been described as an environmental traged...laze. The flames are reportedly spewing out a toxi...explosion from a highly volatile fuel tank led to ...ire service personnel drawn from 16 fire services ...
...that about 34% of the 12 year olds in Scotland are...ation Statistics Division (ISD) has published this...besity is directly connected to latter year // pr...NHS. The country’s political parties are of t...
... in Jharkhand for poor people in the state.// ...perating from January next year. A health de...ls with expert doctors will cover rural areas in 2... and people can avail themselves of these faciliti...
...death of Rene Anderson who took part in a trial wi...ug is derived from the plant, and it has been auth...stered to Rene Anderson for relieving her of painf...monia and kidney failure. The manufacturers of Sat...
Other Medicine News:Health News:EU medical chief says Europe ready for bird flu 2Health News:Firefighters Continue To Battle Blaze 2
BioPette E Electronic Pipettor, 10-200l
Finnpipette BioControl Single Channel, 40-200ul
...or all liquid handling applications in the laborat...ced operating buttons, and various dispensing tech...tting and diluting make this a lab favorite. It in... pipette without any adverse effects on the variet...
... high performance electronic pipetting! , Soft, ...reduce hand fatigue and strain, Stress-free tip ...ing for easy volume identification, Accepts univ... AdvanTip Low Retention and AdvanTip Precision Pip...
Medicine Products: